• Vaccine Name: Influenza virus DNA vaccine encoding HA from Influenza A virus (A/Hong Kong/1/68(H3N2))
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Vaccine Ontology ID: VO_0004015
• Type: DNA vaccine
• Status: Research
• Antigen: Influenza A virus (A/Hong Kong/1/68(H3N2)) HA hemagglutinin
• HA from Influenza A virus (A/Hong Kong/1/68(H3N2)) gene engineering:
  • Type: DNA vaccine construction
  • Description: RNA from a single construct expressing both VEE nonstructural proteins and HK68 HA in place of VEE structural proteins was transfected into baby hamster kidney (BHK) cells by electroporation. Concurrently, RNA from two helper constructs that expressed VEE structural proteins but lacked packaging signals was transfected into BHK cells. Coelectroporation of these three RNA constructs results in the production of VRP that express the nonstructural proteins of VEE and the influenza HA. Supernatants from transfected BHK cells containing VRP were purified and concentrated prior to inoculation (Huber et al., 2006).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0005003
• Immunization Route: Subcutaneous injection

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: For DNA vaccination, 2.5 μg of either HA- or vector control DNA-coated gold particles (1 mg) was delivered at two nonoverlapping sites on the abdomen, using a Helios (Bio-Rad) gene gun, at 21-day intervals. Mice that were boosted with VRP received 1 × 10^6 infectious units expressing either HA or GFP (vector control) delivered subcutaneously in a 10-μl volume in the right rear footpad at 28-day intervals. For an additional control group, mice were inoculated in the right rear footpad with PBS (Huber et al., 2006).
• Challenge Protocol: Lethal influenza challenge
• Efficacy: Vaccination with HA-VRP derived from Influenza A virus (A/Hong Kong/1/68(H3N2)) did not strongly stimulate either neutralizing or IgG1 antibodies but did induce IgG2a antibodies. Expression of IgG2a antibodies in this context correlated with clearance of virus and increased protection against lethal influenza challenge (Huber et al., 2006).